TORL BioTherapeutics LLC (TORL), a biopharmaceutical company focused on developing new biologics for cancer treatment, has announced its public launch and the closing of a US$158 million Series B financing. The financing was led by Goldman Sachs Asset Management, with participation from UC, Office of the Chief Investment Officer, Bristol Myers Squibb, Deep Track Capital, Vertex Ventures HC, Moore Strategic Ventures, Cowen Healthcare Investments, Perceptive Xontogeny Venture Fund, and existing investors including Alexandria Venture Investments and OCV Partners.
Latham & Watkins LLP advises Goldman Sachs in the financing with a deal team led by Bay Area partner Saad Khanani, with Chicago associates Omar Ammash and Jay Trewn. Advise was also provided on tax matters by Bay Area partner Grace Lee and associate Alex Farris, and on benefits & compensation matters by Century City/Bay Area partner Julie Crisp.
